Marc Banjak, Chief Legal Officer of iBio, Inc. (NASDAQ:IBIO), disclosed purchases of company common stock executed on March 26, 2026. The trades consisted of two separate acquisitions: 12,500 shares at $1.6425 per share and 1,434 shares at $1.76 per share, for a combined outlay of $23,055. After these transactions, Banjak is recorded as directly owning 25,000 shares of the company.
The share purchases occurred against a backdrop of notable short-term price movement and longer-term gains. The stock declined 16.75% over the prior week while returning 114.55% over the past six months. iBio’s market capitalization stood at $61.14 million at the time of reporting.
Financial data referenced by InvestingPro indicate a robust current ratio of 9.04 for iBio, a measure suggesting substantial short-term liquidity relative to obligations. InvestingPro is noted as offering 13 additional ProTips for IBIO.
Separately, iBio has advanced its therapeutic pipeline. The company reported preclinical results for IBIO-610, an obesity treatment candidate. In a study involving obese non-human primates, dosing every eight weeks with two administrations produced a 6.7% reduction in visceral fat and a 5.2% reduction in total fat mass. These preclinical outcomes were cited alongside analyst activity.
Jones Trading responded to the data by reiterating a Buy rating and maintaining a $7.00 price target for iBio. The firm also initiated coverage on the company with a Buy rating, highlighting iBio’s extended half-life antibody platform focused on obesity and metabolic conditions. In addition, Jones Trading noted the company’s pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction, with programs targeting myostatin, Activin A and GDF11.
Leerink Partners likewise weighed in, reiterating an Outperform rating with a $5.00 price target and referencing competitor data from Wave Life Sciences in its assessment.
Taken together, the insider purchases, liquidity metric, pipeline updates and analyst commentary provide multiple data points for market participants tracking iBio. The purchases by Banjak and the recent analyst activity coincide with both short-term share price weakness and substantial six-month appreciation.